Bayer Enhances Sensitivity of Automated Immunoassay for Hepatitis B and HIV
Bayer Diagnostics (a division of Bayer HealthCare) has increased the sensitivity of its automated HBc Total and HIV 1/O/2 assays for use on the ADVIA Centaur® Immunoassay System to improve laboratories' detection capability for Hepatitis B and Human Immunodeficiency Virus (HIV) infections.
A revised cut-off point of 0.5 Index has been set for the new HBc Total assay, eliminating the 'equivocal zone' in which results might be subject to varying interpretation when using the previous method. Analytical capacity has been improved from 0.5 - 0.6 PEI IU to 0.2 PEI IU at the cut-off. 100% clinical sensitivity and 99.75% clinical specificity have been established in EU clinical trials, making the assay suitable for the detection of both acute and chronic Hepatitis B infections.
Source: Bayer Diagnostics (UK and Eire) [United Kingdom] View archived contact details
Is a subsidiary/distributor for
Siemens Medical Solutions, USA View company information
Posted: March 21, 2005
[will open your email client]